The controversy around US drug pricing dynamics is adding another dimension of difficulty to deal-making, says Vasilios Kofitsas of Back Bay Life Science Advisors, and an environment where established products may not be as safe an asset class as in the past should drive an increase in deals around emerging technology platforms and earlier-stage candidates.
This could prove a double-edged sword for smaller companies and start-ups, because assets backed by limited data often are assigned...








